Targeted nanotheranostics for future personalized medicine: Recent progress in cancer therapy

Theranostics

Volumn 6, Issue 9, 2016, Pages 1362-1377

  Jo, Sung Duk ^a   Ku, Sook Hee ^a   Won, You Yeon ^a,b   Kim, Sun Hwa ^a   Kwon, Ick Chan ^a,c  

^a Korea Institute of Science and Technology   (South Korea)

^b Purdue University   (United States)

^c Korea University   (South Korea)

Author keywords

Cancer therapy; Nanotheranostics; Personalized medicine

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; GADOLINIUM; NANOMATERIAL; NANOPARTICLE;

BIOLOGICAL MONITORING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; ECHOGRAPHY; FLUORESCENCE IMAGING; GAS; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; REVIEW; THERANOSTIC NANOMEDICINE; TREATMENT RESPONSE; ANIMAL; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; TRENDS;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE; THERANOSTIC NANOMEDICINE;

EID: 84991615377     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.15335     Document Type: Review

References (83)

1. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011; 44: 1029-38
2. Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol. 2013; 24: 1159-66
3. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501: 338-45
4. Lammers T, Rizzo LY, Storm G, Kiessling F. Personalized nanomedicine. Clin Cancer Res. 2012; 18: 4889-94
5. Choi KY, Liu G, Lee S, Chen X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale. 2012; 4: 330-42
6. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010; 62: 1064-79
7. Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics. 2013; 4: 81-9
8. Peer D, Karp JM, Hong S, FaroKHzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2: 751-60
9. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010; 9: 615-27
10. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012; 14: 1-16
11. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991; 88: 11460-4
12. Hatakeyama H, Akita H, Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull. 2013; 36: 892-9
13. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW. Mediating Tumor Targeting Efficiency of Nanoparticles Through Design. Nano Lett. 2009; 9: 1909-15
14. Perry JL, Reuter KG, Kai MP, Herlihy KP, Jones SW, Luft JC, et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 2012; 12: 5304-10
15. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012; 41: 2656-72
16. Huang Y, He S, Cao W, Cai K, Liang XJ. Biomedical nanomaterials for imaging-guided cancer therapy. Nanoscale. 2012; 4: 6135-49
17. Ryu JH, Koo H, Sun IC, Yuk SH, Choi K, Kim K, et al. Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy. Adv Drug Deliv Rev. 2012; 64: 1447-58
18. Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol. 2001; 19: 316-7
19. Ding H, Wu F. Image guided biodistribution and pharmacokinetic studies of theranostics. Theranostics. 2012; 2: 1040-53
20. He X, Wang K, Cheng Z. In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 2: 349-66
21. Na JH, Koo H, Lee S, Min KH, Park K, Yoo H, et al. Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models. Biomaterials. 2011; 32: 5252-61
22. Na JH, Lee SY, Lee S, Koo H, Min KH, Jeong SY, et al. Effect of the stability and deformability of self-assembled glycol chitosan nanoparticles on tumor-targeting efficiency. J Control Release. 2012; 163: 2-9
23. Nam HY, Kwon SM, Chung H, Lee SY, Kwon SH, Jeon H, et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2009; 135: 259-67
24. Kim K, Kim JH, Park H, Kim YS, Park K, Nam H, et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release. 2010; 146: 219-27
25. Chung EJ, Cheng Y, Morshed R, Nord K, Han Y, Wegscheid ML, et al. Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials. 2014; 35: 1249-56
26. Lai J, Shah BP, Garfunkel E, Lee KB. Versatile fluorescence resonance energy transfer-based mesoporous silica nanoparticles for real-time monitoring of drug release. ACS nano. 2013; 7: 2741-50
27. Wu X, Sun X, Guo Z, Tang J, Shen Y, James TD, et al. In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug. J Am Chem Soc. 2014; 136: 3579-88
28. Schellenberger EA, Bogdanov A, Petrovsky A, Ntziachristos V, Weissleder R, Josephson L. Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy. Neoplasia. 2003; 5: 187-92
29. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer. 2008; 8: 94-107
30. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004; 5: 897-907
31. Zhang R, Lu W, Wen X, Huang M, Zhou M, Liang D, et al. Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis. J Nucl Med. 2011; 52: 958-64
32. Zhang R, Huang M, Zhou M, Wen X, Huang Q, Li C. Annexin A5-functionalized nanoparticle for multimodal imaging of cell death. Mol Imaging. 2013; 12: 182-90
33. Lee S, Choi KY, Chung H, Ryu JH, Lee A, Koo H, et al. Real time, high resolution video imaging of apoptosis in single cells with a polymeric nanoprobe. Bioconjug Chem. 2011; 22: 125-31
34. Choi KY, Jeon EJ, Yoon HY, Lee BS, Na JH, Min KH, et al. Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials. 2012; 33: 6186-93
35. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003; 3: 380-7
36. Lee SJ, Koo H, Jeong H, Huh MS, Choi Y, Jeong SY, et al. Comparative study of photosensitizer loaded and conjugated glycol chitosan nanoparticles for cancer therapy. J Control Release. 2011; 152: 21-9
37. Yoon HY, Koo H, Choi KY, Lee SJ, Kim K, Kwon IC, et al. Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials. 2012; 33: 3980-9
38. Shen J, Zhao L, Han G. Lanthanide-doped upconverting luminescent nanoparticle platforms for optical imaging-guided drug delivery and therapy. Adv Drug Deliv Rev. 2013; 65: 744-55
39. Yang D, Ma P, Hou Z, Cheng Z, Li C, Lin J. Current advances in lanthanide ion (Ln(3+))-based upconversion nanomaterials for drug delivery. Chem Soc Rev. 2015; 44: 1416-48
40. Park YI, Lee KT, Suh YD, Hyeon T. Upconverting nanoparticles: a versatile platform for wide-field two-photon microscopy and multi-modal in vivo imaging. Chem Soc Rev. 2015; 44: 1302-17
41. Ma P, Xiao H, Li X, Li C, Dai Y, Cheng Z, et al. Rational design of multifunctional upconversion nanocrystals/polymer nanocomposites for cisplatin (IV) delivery and biomedical imaging. Adv Mater. 2013; 25: 4898-905
42. Tian G, Zheng X, Zhang X, Yin W, Yu J, Wang D, et al. TPGS-stabilized NaYbF4:Er upconversion nanoparticles for dual-modal fluorescent/CT imaging and anticancer drug delivery to overcome multi-drug resistance. Biomaterials. 2015; 40: 107-16
43. Wang C, Tao H, Cheng L, Liu Z. Near-infrared light induced in vivo photodynamic therapy of cancer based on upconversion nanoparticles. Biomaterials. 2011; 32: 6145-54
44. Tian G, Ren W, Yan L, Jian S, Gu Z, Zhou L, et al. Red-emitting upconverting nanoparticles for photodynamic therapy in cancer cells under near-infrared excitation. Small. 2013; 9: 1929-38, 8
45. Park YI, Kim JH, Lee KT, Jeon KS, Bin Na H, Yu JH, et al. Nonblinking and Nonbleaching Upconverting Nanoparticles as an Optical Imaging Nanoprobe and T1 Magnetic Resonance Imaging Contrast Agent. Adv Mater. 2009; 21: 4467-+
46. Yang Y, Sun Y, Cao T, Peng J, Liu Y, Wu Y, et al. Hydrothermal synthesis of NaLuF4:153Sm,Yb,Tm nanoparticles and their application in dual-modality upconversion luminescence and SPECT bioimaging. Biomaterials. 2013; 34: 774-83
47. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008; 7: 591-607
48. Yigit MV, Moore A, Medarova Z. Magnetic nanoparticles for cancer diagnosis and therapy. Pharm Res. 2012; 29: 1180-8
49. Raymond KN, Pierre VC. Next generation, high relaxivity gadolinium MR1 agents. Bioconjug Chem. 2005; 16: 3-8
50. Grange C, Geninatti-Crich S, Esposito G, Alberti D, Tei L, Bussolati B, et al. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma. Cancer Res. 2010; 70: 2180-90
51. Shukla S, Steinmetz NF. Virus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015; 7: 708-21
52. Bruckman MA, Hern S, Jiang K, Flask CA, Yu X, Steinmetz NF. Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents. J Mater Chem B Mater Biol Med. 2013; 1: 1482-90
53. Kobayashi T. Cancer hyperthermia using magnetic nanoparticles. Biotechnol J. 2011; 6: 1342-7
54. Hayashi K, Nakamura M, Sakamoto W, Yogo T, Miki H, Ozaki S, et al. Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. Theranostics. 2013; 3: 366-76
55. Yu MK, Jeong YY, Park J, Park S, Kim JW, Min JJ, et al. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl. 2008; 47: 5362-5
56. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005; 4: 581-93
57. Yang H, Li Y, Li TT, Xu M, Chen Y, Wu CH, et al. Multifunctional Core/Shell Nanoparticles Cross-linked Polyetherimide-folic Acid as Efficient Notch-1 siRNA Carrier for Targeted Killing of Breast Cancer. Sci Rep. 2014; 4
58. Carlsson CA. Imaging modalities in x-ray computerized tomography and in selected volume tomography. Phys Med Biol. 1999; 44: R23-56
59. Xi D, Dong S, Meng XX, Lu QH, Meng LJ, Ye J. Gold nanoparticles as computerized tomography (CT) contrast agents. Rsc Adv. 2012; 2: 12515-24
60. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS nano. 2010; 4: 3689-96
61. Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids. 2014 Aug 5; 3: e182
62. Jaque D, Martinez Maestro L, del Rosal B, Haro-Gonzalez P, Benayas A, Plaza JL, et al. Nanoparticles for photothermal therapies. Nanoscale. 2014; 6: 9494-530
63. Zhang X, Xing JZ, Chen J, Ko L, Amanie J, Gulavita S, et al. Enhanced radiation sensitivity in prostate cancer by gold-nanoparticles. Clin Invest Med. 2008; 31: E160-7
64. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004; Sep; 49: N309-N15
65. Huang P, Bao L, Zhang C, Lin J, Luo T, Yang D, et al. Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials. 2011; 32: 9796-809
66. Phelps ME. PET: The merging of biology and imaging into molecular imaging. J Nucl Med. 2000; 41: 661-81
67. Xiao Y, Hong H, Javadi A, Engle JW, Xu W, Yang Y, et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials. 2012; 33: 3071-82
68. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007; 104: 15549-54
69. Stride E, Saffari N. Microbubble ultrasound contrast agents: a review. Proc Inst Mech Eng H. 2003; 217: 429-47
70. Qin S, Caskey CF, Ferrara KW. Ultrasound contrast microbubbles in imaging and therapy: physical principles and engineering. Phys Med Biol. 2009; 54: R27-57
71. Bloch SH, Wan M, Dayton PA, Ferrara KW. Optical observation of lipid-and polymer-shelled ultrasound microbubble contrast agents. Appl Phys Lett. 2004; 84: 631-3
72. Son S, Min HS, You DG, Kim BS, Kwon IC. Echogenic nanoparticles for ultrasound technologies: Evolution from diagnostic imaging modality to multimodal theranostic agent. Nano Today. 2014; 9: 525-40
73. Min HS, You DG, Son S, Jeon S, Park JH, Lee S, et al. Echogenic Glycol Chitosan Nanoparticles for Ultrasound-Triggered Cancer Theranostics. Theranostics. 2015; 5: 1402-18
74. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65: 271-84
75. Min KH, Min HS, Lee HJ, Park DJ, Yhee JY, Kim K, et al. pH-controlled gas-generating mineralized nanoparticles: a theranostic agent for ultrasound imaging and therapy of cancers. ACS nano. 2015; 9: 134-45
76. Choi BY, Park HJ, Hwang SJ, Park JB. Preparation of alginate beads for floating drug delivery system: effects of CO2 gas-forming agents. Int J Pharm. 2002; 239: 81-91
77. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 1996; 56: 1194-8
78. Wikehooley JL, Haveman J, Reinhold HS. The Relevance of Tumor Ph to the Treatment of Malignant Disease. Radiother Oncol. 1984; 2: 343-66
79. Goss SL, Lemons KA, Kerstetter JE, Bogner RH. Determination of calcium salt solubility with changes in pH and P-CO2, simulating varying gastrointestinal environments. J Pharm Pharmacol. 2007; 59: 1485-92
80. Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer. 2005; 5: 321-7
81. Deckers R, Moonen CT. Ultrasound triggered, image guided, local drug delivery. J Control Release. 2010; 148: 25-33
82. Ma M, Xu H, Chen H, Jia X, Zhang K, Wang Q, et al. A drug-perfluorocarbon nanoemulsion with an ultrathin silica coating for the synergistic effect of chemotherapy and ablation by high-intensity focused ultrasound. Adv Mater. 2014; 26: 7378-85
83. Wang X, Chen HR, Zhang K, Ma M, Li FQ, Zeng DP, et al. An Intelligent Nanotheranostic Agent for Targeting, Redox-Responsive Ultrasound Imaging, and Imaging GuidedHigh-Intensity Focused Ultrasound Synergistic Therapy. Small. 2014; 10: 1403-11